Classification of gastric neuroendocrine tumors and its clinicopathologic significance

Table 1 Antibodies used in the present study

Code	Antigens	Working dilution	Positive control
M869	CgA	1:400	Pancreas
	SP	1:400	Pancreas
A568	GAST	1:300	Gastric antrum
A566	SS	1:400	Pancreas
A756	5-HT	1:20	Small bowel
A576	CT	1:800	Medullary carcinoma of thyroid gland
A619	PP	1:4000	Pancreas
A231	β-HCG	1:800	Human placenta
A571	ACTH	1:800	Pituitary gland
CA-08-219	BOM	1:20000	Duodenum

CgA: Chromogranin A; SP: Synaptophysin; GAST: Gastrin; SS: Somatostatin; 5-HT: Serotonin; CT: Calcitonin; PP: Pancreatic polypeptide; β-HCG: Human chorionic gonadotroph; ACHT: Adrenocorticotrophin; GLU: Glucagon; BOM: Bombesin

Table 2 Immunohistochemical results in 52 cases of gastric tu-mors

	Type 1 (26)				Type 2 (16)				Type 3 (10)
	+	±	-	ND	+	±	-	ND	+	±	-	ND
CgA	24	1	0	1	14	1	0	1	9	1	0	0
SP	16	3	4	3	4	6	4	1	2	5	0	3
GAST	4	2	17	3	2	1	11	2	1	1	8	0
SS	3	0	22	2	1	0	14	3	1	1	8	0
5-HT	10	1	15	0	9	0	5	2	2	0	7	1
CT	1	0	11	14	0	1	4	11	1	1	8	0
β-HCG	5	1	19	1	2	1	12	1	4	2	4	0
ACTH	1	1	12	12	0	1	3	12	2	1	5	2
PP	4	0	21	1	2	1	5	4	1	1	5	3
GLU	0	0	25	1	0	0	15	1	1	0	9	1
BOM	1	1	8	16	0	1	6	9	1	1	7	1

+: Positive; -: Negative; ±: Doubtful; ND: Study not done

Table 3 Clinicopathological characters of gastric neuroendocrine tumors

Type	Sex (F:M)	Mean age (a)	Tumor number	Infiltration	Metastases	Death	Treatment
1	1:3.6	58.2	Single	m, sm		no	Polypectomy
			Multiple	m, sm	3.8%	no	Antrectomy
1	0.6:1	53.8	Single	mp, s	56%	28%	Gastrectomy
3	1:4	62.8	Single	mp, s	80%	70%	Gastrectomy
							Chemotherapy

m: Mucosa; sm: Submucosa; mp: Muscularis propria; s: Sierosa